Our results show that the positive rate of CNN2 antibody in the HCC patients was 54.8%, which was significantly higher than that in the gastric cancer (6.5%), lung cancer (3.2%), rectal cancer (9.7%), hepatitis (3.2%), cirrhosis (3.2%), and normal tissue samples (3.1%) (p < 0.05) (Table 1) (Figure 1C). Here, CNN2 is linked to gastric cancer.